In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the challenges of treating patients with TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting the poor outcomes associated with these patients. Dr Sallman also comments on the need to investigate novel therapeutic strategies for these patients, and highlights agents of interest, including eprenetapopt and magrolimab. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
The challenges of treating TP53-mutated AML and MDS
Теги
Speaker: David SallmanInstitution: Moffitt Cancer CenterEvent: SOHO 2022Format: InterviewSubject: Myelodysplastic SyndromesSubject: LeukemiaSubject: Acute myeloid leukemiaField: PerspectivesField: TreatmentField: Immuno-OncologyMedicines: AntibodiesMedicines: AzacitidineMedicines: VenetoclaxMedicines: EprenetapoptMedicines: MagrolimabMedicines: SabatolimabTP53high-risk
